VMVadim I. Mazurov

Vadim I. Mazurov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vadim I. Mazurov has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic Trajectories, Drug Survival, and Adverse Events in Patients with Difficult-to-Treat Rheumatoid Arthritis in Real-World Clinical Practice

    by Alena I. Zagrebneva, Elena N. Simonova, Yuliya A. Gavrikova, Vladislav V. Dolgov, Anastasiia A. Buianova, Vadim I. Mazurov

    Background/Objectives: Difficult-to-treat rheumatoid arthritis (D2T-RA) affects approximately 11.7% of patients. Real-world data on treatment trajectories, biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), and adverse events (AEs) remain limited. This study evaluated treatment patterns, line survival, and AEs in D2T-RA. Methods: This retrospective study included 97 D2T-RA patients. Treatment-line survival was assessed using Kaplan–Meier analysis with log-rank tests and a cluster-robust Cox proportional hazards model. Generalized estimating equation models (GEE) identified factors associated with AEs. Cluster analysis (K-modes, MCA followed by K-means, and hierarchical clustering) was performed to identify treatment patterns. Results: A median time to first prescription of b/tsDMARDs was 1369 days (IQR 852–2557). Inefficacy was the most common reason for switching (65.8%); csDMARD/GCs were discontinued for inefficacy more frequently than b/tsDMARD (70.1% vs. 61.3%). Among 470 b/tsDMARD-containing treatment lines, interleukin-6 (IL-6) inhibitors were most common (127 lines, 27.0%), followed by tumor necrosis factor-α (TNF-α) inhibitors (109 lines, 23.2%), Janus kinase (JAK) inhibitors (89 lines, 18.9%), rituximab (82 lines, 17.4%), and abatacept (61 lines, 13.0%). The agents used included tocilizumab, levilimab, sarilumab, and olokizumab; adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol; and tofacitinib, baricitinib, and upadacitinib. In adjusted GEE models, treatment type was not a significant predictor of AE occurrence (OR 0.93, 95% CI 0.63–1.36); line number and female sex were independently associated with AEs, and a previous AE increased the risk of AE on the current line (OR 1.72, 95% CI 1.13–2.60; p = 0.011). TNF-α inhibitors were prescribed without concomitant methotrexate in 59 of 109 treatment lines (54.1%). At the final treatment line, lower disease activity was observed with abatacept, levilimab, and olokizumab, whereas higher values were observed with rituximab and etanercept; between-treatment differences were significant for DAS28-ESR (p = 0.0269), but not for CDAI, SDAI, or DAS28-CRP. Cluster analysis identified three exploratory treatment patterns, differing primarily in the use of tsDMARDs and hydroxychloroquine. Conclusions: D2T-RA is characterized by multiple treatment lines and frequent switching due to inefficacy, particularly for csDMARD/GC therapy. Among the targeted therapies evaluated, IL-6 inhibitors and abatacept were associated with lower disease activity at the final treatment line, whereas rituximab and etanercept were associated with higher values; these exploratory observations do not establish comparative effectiveness. The frequent use of TNF-α inhibitors without concomitant methotrexate highlights a potential target for treatment optimization. A history of AEs may help identify patients requiring closer safety monitoring.

  • Charlson comorbidity index in postmenopausal osteoporosis: association with the disease and the location of low-energy fractures

    by Жугрова Елена Сергеевна, Elena S. Zhugrova, Мазуров Вадим Иванович, Vadim I. Mazurov, Беляева Ирина Борисовна, Irina B. Belyaeva, Сапожников Кирилл Викторович, Kirill V. Sapozhnikov

    BACKGROUND: Postmenopausal osteoporosis is characterized by a high burden of comorbid disease, but data on the association of cumulative comorbidity with osteoporosis and with fractures at specific sites in women with PMO remain scarce and inconsistent. AIM: To assess the prevalence and pattern of comorbidity in women with postmenopausal osteoporosis, to determine the association of the charlson comorbidity index with the presence of osteoporosis, and to compare fracture rates at different sites according to age and comorbidity burden. METHODS: The comparative study included 455 women: 355 patients with verified postmenopausal osteoporosis (diagnosed by dual-energy X-ray absorptiometry of the lumbar spine and proximal femur and/or the presence of low-energy fractures) and 100 women without osteoporosis, comparable for age, postmenopausal duration and body mass index. The age-adjusted charlson comorbidity index was calculated in all participants (subgroups ≤3 and 3 points), and the number and site of osteoporotic fractures were recorded. Mann–Whitney U test, chi-square test, Fisher’s exact test, Cochran–Armitage trend test, Spearman correlation, uni- and multivariable logistic regression and ROC analysis (AUC with DeLong 95% CI) were used; multiplicity was controlled with the Holm correction; p 0.05 was considered significant. RESULTS: Median CCI was significantly higher in postmenopausal osteoporosis patients than in controls — 5.0 [4.0; 7.0] vs 2.0 [2.0; 3.0] points (p 0.001). Fracture rates did not differ across age subgroups (60, 60–70 and ≥70 years) at any site (vertebral fractures 87.4, 87.0 and 92.0%; p = 0.510; all p for trend 0.05). Patients with CCI 3 more frequently had ankle fractures (33.2 vs 14.3%; p = 0.002; Holm-adjusted p = 0.012), whereas prior fractures were less frequent (81.2 vs 93.7%; p = 0.015), the latter losing significance after correction for multiplicity (p = 0.075); no differences were found at the other sites, including distal radius fractures (50.3 vs 42.9%; p = 0.331). Discrimination of both age and charlson comorbidity index for individual fracture sites was poor (AUC 0.491–0.591; the acceptable level of 0.7 was not reached for any predictor). Charlson comorbidity index correlated weakly with vertebral fractures (r = 0.195; p 0.001). In univariable models, stage III arterial hypertension (OR 1.9 [1.3; 3.0]), angina pectoris class III (OR 2.0 [1.1; 3.6]), heart failure NYHA class II (OR 2.2 [1.1; 4.5]) and charlson comorbidity index (OR 1.2 [1.1; 1.4] per point) were associated with postmenopausal osteoporosis; in the multivariable model only charlson comorbidity index retained an independent association with the presence of osteoporosis (OR 1.3 [1.02; 1.64]; p = 0.035). CONCLUSION: In women with established postmenopausal osteoporosis, age is not an independent discriminator of fracture rates, whereas an integral assessment of comorbidity retains an independent association with osteoporosis and is more informative than individual diagnoses. However, the poor discrimination of the charlson comorbidity index for individual fracture sites (AUC 0.6) precludes its use as a stand-alone prognostic tool; charlson comorbidity index calculation should therefore be regarded as an additional component of comprehensive risk assessment in patients with postmenopausal osteoporosis.

  • Open Access

    Features of the course and treatment of chronic recurrent multifocal non-bacterial osteomyelitis in adult patients based on the results of 1 year of observation

    by E. P. Bandurko, I. Z. Gaydukova, V. I. Mazurov, Е. П. Бандурко, И. З. Гайдукова, В. И. Мазуров

    Features of the course and treatment of chronic recurrent multifocal non-bacterial osteomyelitis in adult patients based on the results of 1 year of observation | Bandurko | New St. Petersburg Medical Records Особенности течения и лечения хронического множественного небактериального остеомиелита у взрослых пациентов по результатам 1 года наблюдения | Бандурко | Новые Санкт-Петербургские врачебные ведомости

  • Open Access

    Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis

    by Alena I. Zagrebneva, Elena N. Simonova, Yuliya A. Gavrikova, Vladislav V. Dolgov, Anastasiia A. Buianova, Ekaterina D. Glumova, Maria I. Tubalova, Galina S. Koksharova, Artem R. Nurislamov, Vadim I. Mazurov

    Genetic determinants of response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) remain insufficiently characterized. We developed a targeted sequencing panel of candidate immunogenetic variants identified through a literature review and evaluated associations with response to TNF-α inhibitors, response to IL-6 inhibitors, and difficult-to-treat RA (D2TRA). Whole-blood DNA was sequenced using custom hybridization capture on a DNBSEQ-G400 platform (2 × 150 bp). Reads were aligned to hg38 using BWA-MEM, and variants were called with GATK HaplotypeCaller. After quality control, the D2TRA analysis included 154 patients (59 D2TRA and 95 non-D2TRA); drug-response analyses included 66 anti-TNF patients (26 responders, 40 non-responders) and 69 anti-IL-6 patients (29 responders, 40 non-responders). Treatment-response associations were assessed using unadjusted allelic chi-square tests with multiple-testing correction; D2TRA was analyzed using logistic regression adjusted for age, sex, and body mass index. For IL-6 inhibitor response, rs11656130/MAP2K6 (p = 0.0163; FDR = 0.3704) and rs4910008/GALNT18 (p = 0.0212; FDR = 0.3704) were identified, while rs7767069/LINC02549 was associated with TNF-α inhibitor response (p = 0.0171; FDR = 0.5968). For D2TRA, rs1813443 in CNTN5 (OR = 1.85, p = 0.017) and rs12081765, an intergenic variant near LMX1A/RXRG (OR = 0.59, p = 0.028), were nominally associated; neither association remained significant after multiple-testing correction. With the current sample sizes, the study could detect only large genetic effects, and was underpowered for these after Bonferroni correction (α = 0.00143). The findings highlight the limited reproducibility of candidate pharmacogenetic markers in RA and provide a targeted panel and analytical framework for larger replication studies.

  • Secondary haemophagocytic lymphohistiocytosis in blood malignancies. The multicentre retrospective study

    by Vsevolod G. Potapenko, Alina S. Antipova, Julia A. Zhuravleva, Yulia V. Zabutova, Alina Yu. Zavyalova, Irina V. Ishmatova, Elena V. Karyagina, Natalia A. Kotova, Valeria V. Kozyro, Tatiana G. Kulibaba, et al.

    Haemophagocytic syndrome (HPS) or haemophagocytic lymphohistiocytosis is a reaction of severe but ineffective inflammation. Blood malignancies (BlM) are among the frequent causes of HPS in adults. Objective. To analyse survival, causing trigger haemoblastosis, relationship with tumor and efficacy of including etoposide in chemotherapy of patients with secondary HPS-BlM. Material and methods. A retrospective analysis of case histories of patients with BlM complicated by SHPS was performed. The diagnosis of SHPS was verified using H-score and HLH-2004 criteria. Patients with both active malignant process and response to treatment were included in the study. Results. A total of 66 patients, median age 64 (19–90) years, 26 males and 40 females were included in the analysis. Of these, 44 (66.7%) had an active malignant process present. Overall survival in the SHPS-BlM group was 15.1% with a median of 2 (0.2–150) weeks. The prognosis was better in the group treated with etoposide than without it: three-week overall survival was 65.6% (n = 9) and 35%, respectively (p = 0.023). Median survival in the etoposide-free group was 1 (0.2–140) weeks. There were no diff erences in long-term survival depending on the presence of etoposide as part of chemotherapy. In patients without malignancy progression, a possible cause of SHPS was identified in only 8 (36.3%) patients. The overall survival rate was 18.1%, median 12 days (from 3 days to 150 weeks). Conclusion. The structure of patients with SHPS-BlM is dominated by patients with diff use B-cell large cell lymphoma. In the majority of patients SHPS is associated with progression, but in some patients VGFS activity persists despite the achievement of antitumour response. Inclusion of etoposide in therapy leads to an improved prognosis.

  • Open Access

    Experience with rituximab in Purtscher retinopathy in a patient with systemic lupus erythematosus (a clinical case)

    by D. A. Mominova, I. B. Belyaeva, V. I. Mazurov, E. A. Trofimov, V. A. Lila, E. S. Zhugrova

    We present a clinical case of successful use of rituximab (RTM) as part of complex therapy in an Asian female patient with highly active systemic lupus erythematosus (SLE), lupus nephritis, and Purtscher retinopathy (PR) refractory to immunosuppressive therapy. This observation demonstrates not only a reduction in clinical and immunological disease activity parameters and proteinuria, indicating a partial renal response, but also a significant improvement in retinal perfusion according to optical coherence tomography angiography 5 months after RTM infusion, which made it possible to reduce the daily prednisolone dose. This case confirms the efficacy of RTM in refractory SLE-associated PR.

  • Current understanding of the genetic model of systemic sclerosis

    by A.S. Trofimova Trofimova, M.A. Chernyavskaya Chernyavskaya, V.I. Mazurov Mazurov, I.A. Leineman Leineman, E.A. Trofimov Trofimov

  • Open Access

    Updated international recommendations (EULAR 2023) for the treatment of systemic sclerosis

    by A. S. Trofimova, V. I. Mazurov, V. Yu. Myachikova, E. S. Kuvardin, A. L. Maslyanskiy, E. A. Trofimov, В. Ю. Мячикова

    In recent years, significant progress has been achieved in the study of systemic sclerosis (SSc). The treatment of SSc includes conventional synthetic disease-modifying antirheumatic drugs, biologic agents, including anti-B-cell drugs and interleukin-6 inhibitors, as well as antifibrotic agents. Since the last publication of the EULAR recommendations for the treatment of SSc in 2017, changes have occurred; therefore, an update was prepared in which the treatment of the full spectrum of SSc manifestations is considered more broadly. In the updated document 22 recommendations were formulated, and 8 therapeutic domains were identified. The article presents the EULAR 2023 recommendations for the treatment of SSc, as well as promising directions for scientific research.

  • Open Access

    Development of a new algorithm for detecting pulmonary hypertension in patients with systemic sclerosis

    by Nataliya A. Klyaus, Maria A. Simakova, Alexey L. Maslyanskiy, Olga M. Moiseeva, Vadim I. Mazurov, Nikolay T. Gonchar

    BACKGROUND: One of the complications in patients with systemic sclerosis (SSc) that carries an unfavorable prognosis is pulmonary hypertension (PH). Currently existing algorithms for detecting PH in patients with SSc require a large number of expensive tests, which complicates the possibility of their use in routine practice. The introduction of parameters assessed during nailfold capillaroscopy into the diagnostic algorithm may be promising for detecting PH in patients with SSc. AIM: To develop a new algorithm for detecting PH in patients with SSc, incorporating assessment of nailfold capillaroscopy parameters. METHODS: The study included patients with a diagnosis of SSc verified in accordance with the 2013 ACR/EULAR criteria. Patients underwent echocardiographic examination. When indirect signs of PH were detected, right heart catheterization was performed to verify the diagnosis. Patients underwent nailfold capillaroscopy with assessment of capillary density, pattern, distance between capillary loops, width of the capillary loop apex, width of the capillary loop at its widest point, with semiquantitative assessment of capillary density and alterations. To obtain a model and nomogram for predicting the probability of PH in patients with SSc, predictive modeling was performed using the R 4.3.2 environment. RESULTS: Of the 101 patients included in the study, 27 were diagnosed with PH. In patients with PH, greater capillary loop width at the widest point (p = 0.012) and at the apex (p = 0.009), greater distance between capillary loops (p = 0.027), lower capillary density (p 0.001), late scleroderma pattern (p = 0.005), and higher scores for capillary density (p = 0.016) and alterations (p 0.001) were identified. Based on the obtained data and echocardiography data, an algorithm for detecting PH in patients with SSc was developed, with 100% sensitivity [95% CI 87.2–100.0] and 98.6% specificity [95% CI 92.7–100.0]. CONCLUSION: The developed algorithm for detecting PH in patients with SSc has high sensitivity and specificity and requires performing simple non-invasive studies: echocardiography (with measurement of the tricuspid regurgitation gradient and the ratio of the right ventricular diameter to the left ventricular diameter) and nailfold capillaroscopy (with assessment of capillary density and measurement of the capillary loop width at its apex). However, this algorithm requires further external validation to adjust the sensitivity and specificity data of the method.

  • General concepts of refractory and difficult-to-treat rheumatoid arthritis definitions

    by Zagrebneva A.I. Zagrebneva, Simonova E.N. Simonova, GavrikovA Yu.A. GavrikovA, Dolgov V.V. Dolgov V, Samigullina R.R. Samigullina, Mazurov V.I. Mazurov